VivoSim Labs, Inc.(VIVS)

Biotechnology · San Diego, CA

$0.21+0.00 (+0.05%)

Delayed quote: Oct 6, 2026, 2:53 PM EDT

Price/OCF Ratio: N/A

Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.

The Price/OCF ratio is N/A as of 2026-10-06T18:59:09.771Z.

Stored calculation inputs

Calculation as of: 2026-10-06T18:59:09.771Z.

Quote observation: 2026-10-06T18:53:31.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 530,421
TTM operating cash flow · period ending 2026-06-30: -10,100,000

FMP input reference: cafac005872c57a3e4a0b6cd3f460881363b31539507c7b963fc5044b4159481

P/E Ratio|P/FCF Ratio|Operating Cash Flow|Operating Margin|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

VIVS Price/OCF Ratio Metrics

PRICE/OCF RATIO

N/A

VIVS Competitors' Price/OCF Ratio

VIVS

VivoSim Labs, Inc.

Current

Market Cap

$530421.00

Price/OCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

HCWB

HCW Biologics Inc.

vs VIVS

Market Cap

$568741.00

Price/OCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

XRTX

XORTX Therapeutics Inc.

vs VIVS

Market Cap

$484571.00

Price/OCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CDT

CDT Equity Inc.

vs VIVS

Market Cap

$674464.00

Price/OCF Ratio

0.01

TTM Avg

0.16

3Y Avg

40.30

5Y Avg

40.30

NIKI

Niki BioSolutions, Inc.

vs VIVS

Market Cap

$381940.00

Price/OCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

VRAX

Virax Biolabs Group Limited

vs VIVS

Market Cap

$352721.00

Price/OCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

SXTC

China SXT Pharmaceuticals, Inc.

vs VIVS

Market Cap

$755628.00

Price/OCF Ratio

N/A

TTM Avg

758247.42

3Y Avg

2252375.22

5Y Avg

2252375.22

SPRC

SciSparc Ltd.

vs VIVS

Market Cap

$242924.00

Price/OCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

RDGT

Ridgetech, Inc.

vs VIVS

Market Cap

$834466.00

Price/OCF Ratio

N/A

TTM Avg

0.30

3Y Avg

0.38

5Y Avg

0.32

DCOY

Decoy Therapeutics Inc.

vs VIVS

Market Cap

$840882.00

Price/OCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	PRICE/OCF RATIO	TTM	3Y	5Y
VivoSim Labs, Inc. (VIVS)	$530421.00	N/A	N/A	N/A	N/A
HCW Biologics Inc. (HCWB)vs ›	$568741.00	N/A	N/A	N/A	N/A
XORTX Therapeutics Inc. (XRTX)vs ›	$484571.00	N/A	N/A	N/A	N/A
CDT Equity Inc. (CDT)vs ›	$674464.00	0.01	0.16	40.30	40.30
Niki BioSolutions, Inc. (NIKI)vs ›	$381940.00	N/A	N/A	N/A	N/A
Virax Biolabs Group Limited (VRAX)vs ›	$352721.00	N/A	N/A	N/A	N/A
China SXT Pharmaceuticals, Inc. (SXTC)vs ›	$755628.00	N/A	758247.42	2252375.22	2252375.22
SciSparc Ltd. (SPRC)vs ›	$242924.00	N/A	N/A	N/A	N/A
Ridgetech, Inc. (RDGT)vs ›	$834466.00	N/A	0.30	0.38	0.32
Decoy Therapeutics Inc. (DCOY)vs ›	$840882.00	N/A	N/A	N/A	N/A

Operating Cash Flow Valuation

P/OCF Ratio

N/A

P/FCF Ratio

N/A

Price/OCF Ratio Formula & Definition

P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

About VivoSim Labs, Inc.

VivoSim Labs, Inc., a pharmaceutical and biotechnology services company, provides testing of drugs and drug candidates in three-dimensional (3D) human tissue models of liver and intestine. It offers partners liver and intestinal toxicology insights through its new approach methodologies (NAM) models; and bespoke services in the areas of investigational toxicology, mechanism of drug action elucidation, and other applications of complex human tissue models. The company also provides liver toxicology predictive screening and research services, as well as works on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at various stages of drug development; and uses its proprietary technologies to build functional 3D human tissues that mimic key aspects of native human tissue composition, architecture, function, and disease. In addition, it offers 3D human tissue platform that develops novel human normal and disease models using high throughput systems, bioprinted, and flow/stretch capable 3D systems. The company was formerly known as Organovo Holdings, Inc. and changed its name to VivoSim Labs, Inc. in April 2025. VivoSim Labs, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

San Diego, CA

15 employees

vivosim.ai

Healthcare / Biotechnology